IP Library › Granted Patent US 12,178,839
Granted Patent B2
US 12,178,839 · App. 17/288,197 · Granted Dec 31, 2024

Anti-obesity agent, pollakiuria improving agent, and autonomic nervous activity regulator

Inventors: Kohji Ohki (Ibaraki, JP); Koki Sato (Kanagawa, JP); Kazuhito Ohsawa (Kanagawa, JP)
Assignee: ASAHI GROUP HOLDINGS, LTD.
A61K38/10A61P3/04A61P13/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,178,839
App. No.
17/288,197
Granted
Dec 31, 2024
Kind
B2
Abstract

[Problem] The purpose of the present invention is to provide a novel technique associated with anti-obesity improvement. [Solution] The present invention relates to an anti-obesity agent comprising lactononadecapeptide (LNDP, Asn-Ile-Pro-Pro-Leu-Thr-Gln-Thr-Pro-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu) or a salt thereof. The present invention also relates to a pollakiuria improving agent and an autonomic nerve activity regulator each comprising LNDP.

Claims (2)

1. A method for improving pollakiuria, comprising administering a composition comprising an effective amount of a peptide consisting of the amino acid sequence of Asn-Ile-Pro-Pro-Leu-Thr-Gln-Thr-Pro-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu SEQ ID NO: 1 or a salt thereof to a patient-in need of improving pollakiuria.

2. The method according to claim 1 , wherein the peptide or a salt thereof is ingested by the patient in an amount of 0.001 mg to 1 g per day.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2021
From: OHKI, KOHJI; SATO, KOKI; OHSAWA, KAZUHITO
To: ASAHI GROUP HOLDINGS, LTD.
Reel/Frame 056021/0436 →
Priority Claims (1)
JP 2018-202084 · Oct 26, 2018 · national
Continuity (1)
Related Publication 20210401928A1 · Dec 30, 2021